Such treatments may involve epigenetic modifiers as single agents or combined with various established immunotherapies, as DNMT and HDAC inhibition can result in the release of DAMP and the expression of tumor-associated antigens, respectively. This evidence concerns the gene HDAC9 and neoplasm.